ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ALOPRIM
Hyperuricemia
Miscellaneous urogenital disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ALOPRIM Rx

Generic Name and Formulations:
Allopurinol (as sodium) 500mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free.

Company:
Mylan Inc.

Therapeutic Use:

Indications for ALOPRIM:

Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.

Adult:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).

Children:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.

Contraindications:

Asymptomatic hyperuricemia.

Warnings/Precautions:

Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.

Pharmacological Class:

Xanthine oxidase inhibitor.

Interactions:

Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.

Adverse Reactions:

Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.

How Supplied:

Vial—1


Data provided by MPR.

Indications for ALOPRIM:

Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.

Adult:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).

Children:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.

Contraindications:

Asymptomatic hyperuricemia.

Warnings/Precautions:

Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.

Pharmacological Class:

Xanthine oxidase inhibitor.

Interactions:

Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.

Adverse Reactions:

Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.

How Supplied:

Vial—1


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs